Form 4 for MYGN MYRIAD GENETICS INC
Accepted 2026-02-03 00:00:00 ET · period of report 2026-02-02 · accession 0001517026-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-03 | 2026-02-02 | MYGN | Verratti Mark | COO | A - Grant | $0.00 | +32.8K | 414.6K | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | A | A | 32,810 | $0.00 | 414,636 | D | — | — | (F1) Consists of performance-based restricted stock units (PSUs) initially granted on March 15, 2023, subject to accomplishment of pre-determined performance metrics. On February 2, 2026, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 15, 2026. |